Biostax Corp.
BTAX
$0.01
$0.00111.11%
| Weiss Ratings | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.24 | |||
| Price History | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | -47.37% | |||
| 90-Day Total Return | -71.43% | |||
| Year to Date Total Return | -37.11% | |||
| 1-Year Total Return | -80.58% | |||
| 2-Year Total Return | -98.61% | |||
| 3-Year Total Return | -99.39% | |||
| 5-Year Total Return | -99.84% | |||
| 52-Week High % Change | -93.33% | |||
| 52-Week Low % Change | 104.08% | |||
| Price | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.15 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jan 02, 2025 | |||
| 52-Week High Price (Date) | Aug 21, 2024 | |||
| Valuation | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 787.14K | |||
| Enterprise Value | 1.96M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | -48.18% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.16 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -1.69 | |||
| Enterprise Value/EBIT | -1.62 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 83.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 888 391 9355 | |||
| Address | 1317 Edgewater Dr. Orlando, FL 32804 | |||
| Website | www.biostaxcorp.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -198.07% | |||
| Return on Equity | -- | |||
| Income Statement | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -1.16M | |||
| EBIT (TTM) | -1.21M | |||
| Net Income (TTM) | -2.21M | |||
| Net Income Avl. to Common (TTM) | -2.21M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 15.11% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 0.00% | |||
| Balance Sheet | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 0.00 | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 0.00 | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -5.30M | |||
| Current Ratio (Q) | 0.000 | |||
| Book Value Per Share (Q) | -$0.06 | |||
| Total Assets (Q) | 5.50K | |||
| Total Current Liabilities (Q) | 5.31M | |||
| Total Debt (Q) | 1.17M | |||
| Total Liabilities (Q) | 5.31M | |||
| Total Common Equity (Q) | -5.30M | |||
| Cash Flow | BTAX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -153.50K | |||
| Net Change in Cash (TTM) | -17.40K | |||
| Levered Free Cash Flow (TTM) | 555.70K | |||
| Cash from Operations (TTM) | 136.10K | |||
